Biomarkers · Chemical
A plain-language description with its source has not been added for this biomarker yet. What the laboratories say about the tests that measure it is below.
What the laboratory says this test is for
The assay is useful in making the diagnosis of primary hyperparathyroidism, secondary hyperparathyroidism, and a differential diagnosis of hypercalcemia. The assay helps in distinguishing hypercalcemia caused by either primary hyperparathyroidism or malignant disease.
Quest Diagnostics test directory, test code 36736
What the laboratory says this test is for
This panel is for early assessment of metabolic risk, using carefully selected tests that identify early metabolic deviations indicating disease risk. This panel has been selected to identify physiological changes oftentimes evident before the manifestation of common metabolic syndrome risk factors, to aid practitioners in identifying risk and delaying or preventing disease progression.
Quest Diagnostics test directory, test code 39447
What the laboratory says this test is for
The determination of insulin in serum is primarily used for the diagnosis of glycemic disorders in diabetic and pre-diabetic patients in the assessment of insulin resistant syndromes. Insulin is synthesized by the pancreatic beta cell as a precursor, proinsulin. Proinsulin is processed to insulin and C-peptide, a contiguous peptide between the insulin A and B chains, as it passes through the cell. The C-peptide in the proinsulin ensures correct folding and processing of proinsulin as it passes through the cell. Both insulin and C-peptide are released together from the beta cells in response to increased glucose levels. Because of differences in half-life and hepatic clearance, peripheral blood levels of C-peptide and insulin are no longer equimolar but remain highly correlated. A steady-state plasma glucose test in individuals undergoing an insulin suppression test to assess insulin resistance found that the combination of insulin and C-peptide was a better indicator of insulin resistance than either one individually.
Quest Diagnostics test directory, test code 36509
What the laboratory says this test is for
Identifying patients who have metabolic syndrome and who are thus at higher risk of diabetes, coronary heart disease or stroke. Identifying patients who are insulin resistant (fasting insulin at or above the 75th percentile) and who are thus at higher risk of diabetes, coronary heart disease, stroke, or liver disease. Monitoring of risk factors and insulin levels after life style change, medication use, or both.
Quest Diagnostics test directory, test code 91398
Everything above is drawn from the named sources and shown as they published it. Reference ranges belong to the laboratory that issued them and the population it named; they are not a universal normal. This page describes the biomarker in general and does not interpret anyone's result. For your own numbers, talk to a clinician, or use Aumnivida, which reads the same graph next to your records.
Found an error? Write to hello@biomarkerlens.com with the page link and the source that contradicts it.